Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

XX.e

XX - Infections & related conditions

Pneumocystis jiroveci pneumonia

Last update 17/06/2026

The incidence of Pneumocystis pneumonia is increasing (PMID23622345), as more patients with autoimmune- (especially granulomatous polyangiitis-WG), rheumatic and inflammatory conditions including IBD are being exposed to prolonged corticosteroid therapy and immunosuppressive agents. In addition to the risk in transplant recipients and in patients with solid or liquid malignacies (PMID 12974789). Prophylaxis should be discussed on a case by case basis in any patient potentially at risk (PMID 20360202), as Pneumocystis jiroveci pneumonia carries an ominous prognosis in the immunodepressed.with up to 60% mortality (See also under XIp and XIq). Quantitative PCR for Pneumocystis may help separate colonization from an infection (PMID 23990137). Prophylaxis reduces but does not completely eliminate the risk of Pneumocystis pneumonia (PMID 12974789)

Causative drugs

42

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Adalimumab
I.a
I.b
I.c
I.e
I.g
I.n
I.x
I.aa
II.e
III.a
III.d
IV.a
VI.d
VI.m
IX.j
X.b
X.d
X.e
X.l
X.m
X.u
XII.a
XII.s
XVI.e
XVI.k
XIX.a
XIX.d
XIX.f
XX.a
XX.b
XX.c
XX.e
XX.f
XX.g
XX.y
XX.z
Adrenocorticotropic hormone (ACTH)
XX.b
XX.c
XX.e
Alemtuzumab
I.a
I.b
II.a
II.e
III.a
IV.a
VII.b
X.e
X.i
X.m
X.ae
X.ap
XIX.a
XIX.o
XX.b
XX.e
XX.h
XX.m
XXI.b
Amiodarone
I.a
I.b
I.c
I.d
I.e
I.f
I.g
I.i
I.l
I.m
I.t
I.v
I.x
I.aa
I.ab
I.ap
I.au
I.ay
I.az
II.e
II.m
III.a
III.c
IV.a
IV.k
IV.ab
V.a
VI.a
VI.c
VI.d
VI.u
VII.a
VII.i
IX.a
IX.d
IX.ai
X.d
X.f
X.s
XI.c
XI.g
XII.a
XII.c
XII.f
XII.n
XII.o
XII.q
XII.v
XII.ah
XII.aw
XV.g
XVI.b
XVI.i
XVI.j
XVI.n
XVI.s
XVI.w
XVI.x
XVI.ab
XVI.ac
XVI.ba
XVI.bb
XVI.bn
XVI.bt
XVI.bv
XVI.cb
XVII.b
XVII.j
XVII.k
XVII.p
XVIII.a
XVIII.b
XVIII.c
XVIII.e
XVIII.f
XVIII.m
XVIII.p
XIX.a
XIX.b
XIX.c
XIX.d
XIX.e
XIX.k
XIX.o
XIX.q
XIX.r
XIX.v
XIX.w
XIX.aa
XIX.ae
XIX.ag
XIX.aj
XIX.ak
XIX.bm
XX.e
Antilymphocyte therapies
II.e
XX.b
XX.e
Azathioprine
I.a
I.b
I.c
I.e
I.g
I.m
I.n
I.r
I.ai
II.e
III.a
V.a
X.i
X.q
XII.i
XVIII.a
XIX.a
XIX.f
XIX.o
XIX.w
XIX.ck
XX.e
XX.h
XXI.b
Belatacept
I.b
II.e
XX.e
XX.m
Bendamustine
IX.h
XX.b
XX.e
XX.af
Bortezomib
I.a
I.b
I.e
I.m
II.e
III.a
VII.b
X.c
X.p
X.q
XII.a
XII.d
XII.g
XII.r
XII.t
XII.ak
XIX.a
XIX.d
XX.e
XX.h
XX.j
Brentuximab vedotin
I.a
I.b
I.c
I.d
II.e
IV.a
X.i
XI.b
XIX.b
XX.e
XXIII.c
Chemotherapy, antineoplastic
I.a
I.b
I.c
I.e
I.f
I.g
I.i
I.l
I.m
I.n
I.o
I.w
I.x
I.y
I.z
I.ab
I.ae
I.av
II.a
II.b
II.e
II.f
III.a
IV.a
IV.j
V.a
V.g
VI.a
VI.f
VI.ac
VII.b
VII.c
VII.f
VIII.a
VIII.h
IX.f
IX.j
IX.o
X.c
X.d
X.f
X.i
X.m
X.p
XI.b
XI.l
XI.t
XII.a
XII.b
XII.c
XII.f
XII.g
XII.h
XII.m
XII.n
XII.t
XII.ak
XVI.ac
XVI.ad
XVI.bh
XVI.bp
XVI.by
XVIII.g
XIX.d
XIX.e
XIX.o
XIX.q
XIX.x
XIX.ba
XIX.bd
XIX.bx
XX.b
XX.c
XX.e
XX.g
XX.j
XX.r
XX.ae
XXI.a
XXI.b
XXI.d
Cladribine
I.a
I.b
I.e
XIX.k
XX.b
XX.e
XX.g
XX.j
XX.q
XXI.b
Copanlisib
I.a
I.b
XX.b
XX.e
Corticosteroids, inhaled (ICS)
IV.a
IV.b
IV.ab
V.d
V.j
V.x
V.ah
X.j
XI.v
XI.w
XI.ad
XI.af
XX.a
XX.b
XX.c
XX.e
XX.g
XX.h
XX.k
XX.m
XX.w
Corticosteroids, systemic (oral, parenteral)
I.z
II.a
II.b
III.a
III.b
IV.b
V.k
VII.a
VII.e
VII.ac
VIII.c
VIII.g
VIII.h
VIII.j
IX.a
IX.f
IX.m
IX.p
IX.v
X.f
X.p
X.au
X.bb
XI.s
XI.ad
XI.af
XI.aq
XII.a
XII.n
XII.x
XVI.av
XVI.aw
XX.a
XX.b
XX.c
XX.d
XX.e
XX.g
XX.j
XX.m
XX.o
XX.r
XX.u
XX.v
XX.ah
Loading more…